domingo, 21 de enero de 2018

Cancer transcriptome profiling at the juncture of clinical translation. - PubMed - NCBI

Cancer transcriptome profiling at the juncture of clinical translation. - PubMed - NCBI



 2018 Feb;19(2):93-109. doi: 10.1038/nrg.2017.96. Epub 2017 Dec 27.

Cancer transcriptome profiling at the juncture of clinical translation.

Cieślik M1,2Chinnaiyan AM1,2,3,4,5.

Abstract

Methodological breakthroughs over the past four decades have repeatedly revolutionized transcriptome profiling. Using RNA sequencing (RNA-seq), it has now become possible to sequence and quantify the transcriptional outputs of individual cells or thousands of samples. These transcriptomes provide a link between cellular phenotypes and their molecular underpinnings, such as mutations. In the context of cancer, this link represents an opportunity to dissect the complexity and heterogeneity of tumours and to discover new biomarkers or therapeutic strategies. Here, we review the rationale, methodology and translational impact of transcriptome profiling in cancer.

PMID:
 
29279605
 
DOI:
 
10.1038/nrg.2017.96

No hay comentarios:

Publicar un comentario